参考文献/References:
[1] Katz JD,Suriani RJ. A review of transcatheter treatment of valvular heart disease[J]. JAMA,2021,326(17):1747.
[2] Hwang MH,Burchfiel CM,Sethi GK,et al. Comparison of the causes of late death following aortic and mitral valve replacement[J]. J Heart Valve Dis,1994,3(1):17-24.
[3] Rush CJ,Berry C,Oldroyd KG,et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction[J]. JAMA Cardiol,2021,6(10):1130-1143.
[4] Shiba M,Kato T,Morimoto T,et al. Prognostic value of reduction in left atrial size during a follow-up of heart failure:an observational study[J]. BMJ Open,2021,11(2):e044409.
[5] Uretsky S,Wolff SD. Cardiovascular magnetic resonance in valvular heart disease-related heart failure[J].?Heart Fail Clin,2021,17(1):103-108.
[6] Sun Q,Jiang S,Wang X,et al. A prediction model for major adverse cardiovascular events in patients with heart failure based on high-throughput echocardiographic data[J]. Front Cardiovasc Med,2022,9:1022658.
[7] Ikonomidis I,Aboyans V,Blacher J,et al. The role of ventricular-arterial coupling in cardiac disease and heart failure:assessment,clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases,European Association of Cardiovascular Imaging,and Heart Failure Association[J].?Eur J Heart Fail,2019,21(4):402-424.
[8] Castiglione V,Aimo A,Vergaro G,et al. Biomarkers for the diagnosis and management of heart failure[J]. Heart Fail Rev,2022 ,27(2):625-643.
[9] Perrone MA,Storti S,Salvadori S,et al. Cardiac troponins:are there any differences between T and I?[J]. J Cardiovasc Med(Hagerstown),2021,22(11):797-805.
[10] Nitsche C,Koschutnik M,Kammerlander A,et al. Gender-specific differences in valvular heart disease[J]. Wien Klin Wochenschr,2020,132(3-4):61-68.
[11] Surina S,Fontanella RA,Scisciola L,et al. miR-21 in human cardiomyopathies[J]. Front Cardiovasc Med,2021,8:767064.
[12] Seferovic PM,Ponikowski P,Anker SD,et al. Clinical practice update on heart failure 2019:pharmacotherapy,procedures,devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology[J].?Eur J Heart Fail,2019,21(10):1169-1186.
[13] Paolillo S,Dell’Aversana S,Esposito I,et al. The use of β-blockers in patients with heart failure and comorbidities:doubts,certainties and unsolved issues[J].?Eur J Intern Med,2021,88:9-14.
[14] Ren K,Feng J,Yang X,et al. Efficacy of metoprolol combined with torasemide in elderly patients with degenerative valvular heart disease and heart failure and its influence on NT-proBNP levels[J]. Pak J Med Sci,2023,39(4):945-949.
[15] Cheng X,Zhu M,Liu Q,et al. Effectiveness of metoprolol in improving cardiac and motor functions in patients with chronic heart failure:a prospective study[J]. Drug Des Devel Ther,2020,14:3485-3494.
[16] Grassi G. Metoprolol in the treatment of cardiovascular disease:a critical reappraisal[J]. Curr Med Res Opin,2018,34(9):1635-1643.
[17] Doumas M,Imprialos KP,Stavropoulos K. Metoprolol for the prevention of exacerbations of COPD[J].?N Engl J Med,2020,382(14):1374-1375.
[18] Mascolo A,di Mauro G,Cappetta D,et al. Current and future therapeutic perspective in chronic heart failure[J]. Pharmacol Res,2022,175:106035.
[19] McMurray JJ,Packer M,Desai AS,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014,371(11):993-1004.
[20] Bulsara KG,Makaryus AN. Candesartan[M]. In: StatPearls. Treasure Island(FL):StatPearls,2023.
[21] 孙在茂. 坎地沙坦酯联合氢氯噻嗪治疗老年性退行性心瓣膜病心力衰竭的临床观察[J]. 中国药房,2015,26(21):2922-2924.
[22] Hammer F,Buehling SS,Masyout J,et al. Protective effects of spironolactone on vascular calcification in chronic kidney disease[J]. Biochem Biophys Res Commun,2021,582:28-34.
[23] Aguilar Medina DA,Cazarín J,Maga?a M. Spironolactone in dermatology[J]. Dermatol Ther,2022,35(5):e15321.
[24] 姚宏英,杨勇,洪涛,等. 比索洛尔、依那普利及螺内酯三联疗法对风湿性心脏瓣膜病合并慢性心力衰竭患者LVEF、LVEDD以及LVESD的影响[J]. 中国老年学杂志,2016,36(16):3944-3945.
[25] Shringi S,Joshi S,Suffredini JM,et al. Long-term ambulatory intravenous milrinone therapy in advanced heart failure[J]. Heart Lung Circ,2022,31(12):1630-1639.
[26] Hutchings DC,Anderson SG,Caldwell JL,et al. Phosphodiesterase-5 inhibitors and the heart:compound cardioprotection?[J]. Heart,2018,104(15):1244-1250.
[27] 王小波,郑在勇,吕明明,等. SGLT2抑制剂治疗心力衰竭疗效的系统评价[J]. 西部医学,2022,34(3):406-410.
[28] Vahanian A,Beyersdorf F,Praz F,et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J].?Eur Heart J,2022,43(7):561-632.
[29] Zhang L,Zheng X,Long Y,et al. D-dimer to guide the intensity of anticoagulation in Chinese patients after mechanical heart valve replacement:a randomized controlled trial[J]. J Thromb Haemost,2017,15(10):1934-1941.
[30] Stassano P,di Tommaso L,Monaco M,et al. Aortic valve replacement:a prospective randomized evaluation of mechanical versus biological valves in patients ages 55 to 70 years[J]. J Am Coll Cardiol,2009,54(20):1862-1868.
[31] McDonagh TA,Metra M. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). With the special contribution of the Heart Failure Association(HFA) of the ESC[J].?Eur J Heart Fail,2022,24(1):4-131.
[32] Imamura T,Tanaka S,Ushijima R,et al. The implication of optimal heart rate in patients with systolic dysfunction following TAVR[J].?J Card Surg,2021,36(4):1328-1333.
[33] Mack MJ,Lindenfeld J,Abraham WT,et al. 3-Y ear outcomes of transcatheter mitral valve repair in patients with heart failure[J]. J Am Coll Cardiol,2021,77(8):1029-1040.
[34] Ailawadi G,Lim DS,Mack MJ,et al. One-year outcomes after MitraClip for functional mitral regurgitation[J]. Circulation,2019,139(1):37-47.
[35] Bloomfield P,Wheatley DJ,Prescott RJ,et al. Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses[J]. N Engl J Med,1991,324(9):573-579.
[36] Hossain R,Chelala L,Sleilaty G,et al. Preprocedure CT findings of right heart failure as a predictor of mortality after transcatheter aortic valve replacement[J].?AJR Am J Roentgenol,2021,216(1):57-65.
[37] Dong M,Wang L,Tse G,et al. Effectiveness and safety of transcatheter aortic valve replacement in elderly people with severe aortic stenosis with different types of heart failure[J]. BMC Cardiovasc Disord,2023,23(1):34.
[38]Menasché P,Vanneaux V,Hagège A,et al. Transplantation of human embryonic stem?cell-derived cardiovascular progenitors for severe?ischemic left?ventricular dysfunction[J].?J Am Coll Cardiol,2018,71(4):429-438.
[39] Nguyen PK,Rhee JW,Wu JC. Adult stem cell therapy and heart failure,2000 to 2016:a systematic review[J]. JAMA Cardiol,2016,1(7):831-841.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(5):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(5):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(5):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(5):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(5):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]